ALZN earnings date and last-quarter result: next report 2026-09-09, last quarter miss, P/E -0.29. Updated 2026-07-23.
Alzamend Neuro (ALZN) Research Hub
Alzamend Neuro (ALZN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.14 USD (+0.88%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.29, market cap 0.00B. This hub links to the full technical, earnings and options research available for ALZN.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.14 USD (+0.88%) |
| 52-week range | 1.06 USD – 1.95 USD |
| Trend regime | Range |
| 14-day RSI | 24.4 (Oversold) |
| Trailing P/E | -0.29 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-09 |
Available research for ALZN
Covered Call on ALZN: how it works, illustrative setup around the real 1.14 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ALZN: how it works, illustrative setup around the real 1.14 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ALZN: how it works, illustrative setup around the real 1.14 USD price, max profit/loss, breakeven and when to use it. Educational.
ALZN technical analysis: range, last 1.14 USD, RSI 24.4, 52w range 1.06 USD–1.95 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ALZN in?
Alzamend Neuro (ALZN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ALZN in an uptrend or downtrend?
As of 2026-10-26, ALZN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ALZN's trailing P/E ratio?
ALZN's trailing P/E is -0.29, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does ALZN next report earnings?
ALZN is next scheduled to report earnings on 2026-09-09.